Skip to main content

Bienaime Jean Jacques's Form 4 filing

Biomarin Pharmaceutical Inc (BMRN) · filed Jan 11, 2024

Accession no.
0001048477-24-000002
Filed
Jan 11, 2024
Trade date
Jan 8-10, 2024
Filing delay
3 daysLate
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.95M. It was filed 3 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bienaime Jean JacquesCIK 0001221590Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 8, 2024Common StockLLess common codeAcquired+50$99.05+$4,952.5425,162Direct
Jan 9, 2024Common StockMOption exerciseAcquired+10,000$63.10+$631,000435,162Direct
Jan 9, 2024Common StockSSaleDisposed−10,000$98.19−$981,900425,162Direct
Jan 10, 2024Common StockMOption exerciseAcquired+10,000$63.10+$631,000435,162Direct
Jan 10, 2024Common StockSSaleDisposed−10,000$96.38−$963,800425,162Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 9, 2024Common StockMOption exerciseDisposed−10,000$0.00$0171,000Direct
Jan 10, 2024Common StockMOption exerciseDisposed−10,000$0.00$0161,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)